JW Life Science

JW Life Science EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of JW Life Science (234080.KS) as of Oct 21, 2026 is 7.24. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 5.65 — a change of 28.16% (higher).

EV/FCF

7.24

YoY

28.16%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of JW Life Science is 2025 7.24 . EV/FCF (Enterprise Value to Free Cash Flow) of JW Life Science was 2024 5.65 . It decreases by 28.16% higher compared to the previous year.

The JW Life Science EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
9.63 KRW
Jan 1, 2019
14.87 KRW
Jan 1, 2020
6.41 KRW
Jan 1, 2021
17.68 KRW
Jan 1, 2022
38.76 KRW
Jan 1, 2023
6.70 KRW
Jan 1, 2024
5.65 KRW
Jan 1, 2025
7.24 KRW
The JW Life Science EV/FCF history
YEAREV/FCFYoY
7.24+28.16%
5.65-15.70%
6.70-82.72%
38.76+119.27%
17.68+175.63%
6.41-56.87%
14.87+54.42%
9.63-50.15%
19.32-80.22%
97.66+31.72%
74.14+56.79%
47.29—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JW Life Science Stock analysis

What does JW Life Science do? JW Life Science Corp. manufactures intravenous fluids including basic IV fluids with water, electrolytes, and glucose, nutrient infusion solutions containing amino acids, lipids, proteins, vitamins, and minerals, and special infusion solutions for specific medical cases. The company produces total parenteral nutrition (TPN) products as part of its manufacturing focus. The primary buyers of these products are healthcare providers and hospitals requiring intravenous treatments for patient care. The company serves the medical sector by providing essential fluid and nutrition solutions for clinical use. The firm's product segments are defined by the types of IV fluids and TPN solutions they produce, targeting healthcare institutions that administer intravenous therapies. Basic IV fluids are used for general hydration and electrolyte balance, while nutrient infusion solutions support patient nutrition in critical care settings. Special infusion solutions address unique medical conditions requiring tailored treatments. The company's offerings are integral to hospital and clinic operations in delivering patient care. JW Life Science Corp. generates revenue through the sale of its manufactured intravenous fluid products to healthcare facilities. The company's business model relies on consistent demand for IV fluids and TPN solutions within the medical industry. Its products are distributed to hospitals and clinics that require these essential medical supplies for patient treatment protocols. JW Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JW Life Science stock

EV/FCF (Enterprise Value to Free Cash Flow) of JW Life Science is 7.24 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of JW Life Science changed from 5.65 to 7.24, representing a 28.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) JW Life Science since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s JW Life Science with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — JW Life Science

All Key Metrics — JW Life Science